A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).
D. E. Rathkopf
No relevant relationships to disclose
D. C. Danila
No relevant relationships to disclose
S. F. Slovin
No relevant relationships to disclose
M. J. Morris
No relevant relationships to disclose
J. E. Steinbrecher
No relevant relationships to disclose
Y. Chen
No relevant relationships to disclose
M. Fleisher
No relevant relationships to disclose
S. M. Larson
No relevant relationships to disclose
C. L. Sawyers
Consultant or Advisory Role - Aragon Pharmaceuticals (U)
Stock Ownership - Aragon Pharmaceuticals
H. I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U)